Table 2. Averages of clinical baseline parameters and evolution of heart rate and respiratory rate of dogs with stage B2 and C myxomatous mitral valve disease with omega-3 dietary supplementation or not for 12 months.
| Control | Omega-3 | ||||||
|---|---|---|---|---|---|---|---|
| Variables | Times | n | Averages | n | Averages | p* | p** |
| HR (bpm) | T0 | 13 | 149.00 ± 28.00 | 16 | 154.00 ± 45.00 | 0.363 | 0.983 |
| T3 | 10 | 144.00 ± 23.00 | 10 | 146.00 ± 40.00 | 0.853 | ||
| T6 | 9 | 139.00 ± 27.00 | 8 | 138.00 ± 29.00 | 0.673 | ||
| T9 | 9 | 137.00 ± 14.00 | 8 | 144.00 ± 32.00 | 0.606 | ||
| T12 | 7 | 140.00 ± 28.00 | 6 | 148.00 ± 30.00 | 0.755 | ||
| p*** | 0.971 | 0.711 | |||||
| RR (mpm) | T0 | 13 | 109.00 ± 63.00 | 16 | 93.00 ± 55.00 | 0.525 | 0.370 |
| T3 | 10 | 64.00 ± 49.00 | 10 | 108.00 ± 56.00 | 0.853 | ||
| T6 | 9 | 64.00 ± 40.00 | 8 | 84.00 ± 56.00 | 0.370 | ||
| T9 | 9 | 70.00 ± 58.00 | 8 | 85.00 ± 61.00 | 0.167 | ||
| T12 | 7 | 69.00 ± 50.00 | 6 | 111.00 ± 43.00 | 0.530 | ||
| p*** | 0.176 | 0.676 | |||||
HR: Heart rate; bpm: Beats per minute; RR: Respiratory rate; mpm: Movements per minute; p*: Difference between treatments; p**: Difference between times; p***: Difference in treatment by time interaction Kruskal-Wallis test at 5% of significance.